key: cord-0967034-adfzatpn
authors: Kolivras, Athanassios; Thompson, Curtis; Pastushenko, Ievgenia; Mathieu, Marisa; Bruderer, Pascal; de Vicq, Marine; Feoli, Francesco; Harag, Saadia; Meiers, Isabelle; Olemans, Catherine; Sass, Ursula; Dehavay, Florence; Fakih, Ali; Lam‐Hoai, Xuan‐Lan; Marneffe, Alice; Van De Borne, Laura; Vandersleyen, Valerie; Richert, Bertrand
title: A clinicopathological description of COVID‐19‐induced chilblains (COVID‐toes) correlated with a published literature review
date: 2021-08-09
journal: J Cutan Pathol
DOI: 10.1111/cup.14099
sha: 88e0a146a3bd06a90676c37ff3a000dbcb7f6785
doc_id: 967034
cord_uid: adfzatpn

BACKGROUND: The abundance of publications of COVID‐19‐induced chilblains has resulted in a confusing situation. METHODS: This is a prospective single‐institution study from 15 March to 13 May 2020. Thirty‐two patients received PCR nasopharyngeal swabs. Of these, 28 patients had a thoracic CT‐scan, 31 patients had blood and urine examinations, 24 patients had skin biopsies including immunohistochemical and direct immunofluorescence studies, and four patients had electron microscopy. RESULTS: COVID‐19‐induced chilblains are clinically and histopathologically identical to chilblains from other causes. Although intravascular thrombi are sometimes observed, no patient had a systemic coagulopathy or severe clinical course. The exhaustive clinical, radiological, and laboratory work‐up in this study ruled‐out other primary and secondary causes. Electron microscopy revealed rare, probable viral particles whose core and spikes measured from 120 to 133 nm within endothelium and eccrine glands in two cases. CONCLUSION: This study provides further clinicopathologic evidence of COVID‐19‐related chilblains. Negative PCR and antibody tests do not rule‐out infection. Chilblains represent a good prognosis, occurring later in the disease course. No systemic coagulopathy was identified in any patient. Patients presenting with acral lesions should be isolated, and chilblains should be distinguished from thrombotic lesions (livedo racemosa, retiform purpura, or ischemic acral necrosis).

In a short period, numerous publications have followed the initial report 1 correlating all acral eruptions with disease severity. 4 However, chilblains have never been reported as an isolated cutaneous finding in severely ill patients. [5] [6] [7] [8] [9] Further confusion has ensued after identification of microthrombi in skin biopsies, again assuming coagulation activation. 10 Numerous authors have even concluded that COVID-19-induced chilblains are unrelated to infection because of negative PCR swabs and serologies.

Some have even attributed chilblains to a senescent lifestyle during the quarantine. [11] [12] [13] [14] The abundance of publications and lack of clinicopathological correlation have resulted in an incomprehensible situation for dermatopathologists and clinicians.

The objectives of this study are to provide (1) a thorough assessment of a set of patients with clinical, histopathological, radiological, and laboratory analyses, and (2) an interpretation of our findings based on a critical synthesis of published literature. We will show that the most important component in the work-up of a patient presenting with acral, vasculitic lesions, possibly from COVID-19, is ruling-out a hypercoaguable state, which has a poor prognosis. In contrast, young people presenting with COVID-19-induced chilblains are usually asymptomatic or pauci-symptomatic, representing a late-stage of the infection with a good prognosis. 

The required inclusion criteria were as follows: (1) 33.22) ; concurrent (10 pt); and following chilblains by 5 days (3 pt) (range from 2 to 7 days, mean 5, SD 2.65, 95% CI from 1.57 to 11.57). General symptoms were fever (1 pt >38 C), sore throat (3 pt), headache (7 pt), dry cough (8 pt), dyspnea (2 pt), nasal congestion (4 pt), loss of taste (1 pt), anosmia (1 pt), abdominal pain (2 pt), diarrhea (2 pt), myalgia (5 pt), night sweats (1 pt), fatigue (4 pt), and weight loss (1 pt). Nasopharyngeal swab was positive in two patients (1 pt excluded); All thoracic CT scans were normal; COVID-19 serology positive in four patients after 2 weeks (three with IgA and one with IgG and IgA) and in two patients after 4 weeks (only IgA). Blood and urine tests were normal or negative after exclusion criteria except increased erythrocyte sedimentation rate ( Data are included for patients before and after three patients were excluded from the study. In this study, the cutaneous lesions were all located exclusively on the feet. One patient had both hand and feet involvement but was excluded because of identification of anti-scl70 antibodies. All lesions were located on the dorsum of the digits and particularly on the distal phalanges except in two cases with eroded crusted lesions on the ventral side of the digits. A set of clinical photos are included (A-D). A, A diffuse edematous lesion on an erythematous background. B, Individual, erythematous, violaceous and purpuric papules, and plaques, with fewer macules. C, Necrotic bulla (arrow) on an erythemato-violaceous background. D, Resolving lesions with residual erosions and desquamation 3 | RESULTS

Summarized clinical and laboratory findings are presented in Table 1 and Figure 1 , and correlation between clinical findings and clinical evolution is presented in Figure 2 .

H&E, PAS, and Alcian-blue stain photomicrographs are shown in Figure 3 . A summary of histopathologic features is presented in Table 2 ; IHC findings are shown in Figure 4 ; and DIF findings are shown in Table 3 . Finally, a clinico-histopathological correlation of the most significant results is presented in Figure 5 . 

Our findings relate to the expansive existing, published literature to date as follows: [15] [16] [17] 20 which were excluded in our study.

In two of our cases, EM identified rare structures highly suspicious for COVID-19 in endothelium and eccrine glands ( Figure 6 ). We did not employ IHC diagnostics, but IHC has been reported by Notes: A skin biopsy was performed in 24 patients, but three patients were excluded because of a positive ANA. Thus, 21 patients are reported. Of note, the exclusion of these three patients did not statistically affect our results. Each histopathologic feature is recorded as "Present" or "Absent" in a percentage of the patients. Subcharacteristics are noted in parentheses.

papillary dermal edema with extravasated erythrocytes, a superficial and deep perivascular lymphocytic infiltrate involving post-capillary venule walls, and a deep, peri-eccrine lymphocytic infiltrate. 10, [33] [34] [35] [36] [37] [38] Histopathologic distinction between primary (cold-induced) and secondary (chilblain lupus) chilblains remains challenging and controversial, the former being favored by marked papillary dermal edema, limited vacuolar interface dermatitis, and the presence of a peri-eccrine lymphocytic infiltrate. [39] [40] [41] [42] [43] In our cases, cold-induced chilblains seemed unlikely as papillary dermal edema was absent in 72% of our cases, vacuolar interface changes were present in all cases, and DIF was negative in all cases (Tables 2 and 3 ). However, we do not believe that the distinction between primary and secondary chilblains can be made based only upon histopathological examination without taking into consideration the clinical context. Notable among our findings was thickening of post-capillary venule walls ( Figure 3D,E) , which has been observed by others, and generous peri-eccrine mucin deposition ( Figure 3H ). These findings could be explained by the known presence of the angiotensin-converting enzyme-2 (ACE2) receptor on endothelial cells and eccrine glands, because the ACE2 receptor has been identified as the binding target for COVID- 19. 44 Of note, the chilblains are histopathologically similar to the reported "erythema multiforme-like" eruption with confluent, targetoid lesions, usually on hands and elbows. 45 A, Endothelial cell. Probable viral particle (arrow) with a core and spikes measuring 0.099 μm and 0.031 μm, respectively (Â8000); B, Endothelial cell. Probable viral particles (arrow) with a core and spikes measuring 0.101 and 0.032 μm, respectively (left particle), and 0.089 and 0.032 μm, respectively (right particle) (Â8000); C, Endothelial cell. Probable viral particle (arrow) with a core and spikes measuring 0.95 and 0.027 μm, respectively (Â8000); D, Eccrine gland cell. Probable viral particle (arrow) with a core and spikes measuring 0.098 and 0.022 μm, respectively (Â8000); E, Eccrine gland cell with magnification. Probable viral particle (arrow) with a core and spikes measuring 0.98 and 0.030 μm, respectively (Â8000). F, Eccrine gland cell. Probable viral particle (arrow) with a core and spikes measuring 0.101 and 0.030 μm, respectively (Â8000) later after mild symptoms have been supported by others. 5, 48 Despite the absence of disease severity in a subset of patients, COVID-toes may persist more than 60 days (instead of 15 days), representing persistent inflammation. 61 Given the histopathologic similarity of the reported erythema multiforme-like eruption with also negative PCR swabs, the erythema multiforme-like eruption is also a good prognostic clue. All of these patients, however, are important in reaching "herd immunity" and ending the pandemic. 48 showed an indolent disease course. A presentation of any acral lesion during this period should signal the need to identify and isolate an asymptomatic patient, but dermatologists should distinguish simple chilblains from thrombotic lesions, such as distal livedo racemosa, retiform purpura, and ischemic acral necrosis, because the latter may portend a more severe clinical course.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-2542-6935

Curtis Thompson https://orcid.org/0000-0003-0788-346X

Ievgenia Pastushenko https://orcid.org/0000-0001-5421-8839

Bertrand Richert https://orcid.org/0000-0002-4144-6602

COVID-19) infection-induced chilblains: a case report with histopathological findings

Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak

Algorithm for the classification of COVID-19 rashes

Diagnostic value of skin manifestation of SARS-CoV-2 infection

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic

Acral cutaneous lesions in the time of COVID-19

Chilblain-like lesions on feet and hands during the COVID-19 pandemic

Novel outbreak of acral lesions in times of COVID-19: a description of 74 cases from a tertiary university hospital in Spain

COVID toes"): histologic, immunofluorescence, and immunohistochemical study of 17 cases

Evaluation of chilblains as a manifestation of the COVID-19 pandemic

Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic

Major cluster of paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown

Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection

Positive Epstein-Barr virus detection in corona virus disease 2019 (COVID-19) patients

Foot manifestations in a patient with COVID-19 and Epstein-Barr virus: a case study

Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19

Chilblain lupus erythematosus -a review of literature

Interféronopathies de type I

Major cluster of chilblain cases in a cold dry Western Australian winter. J Paediatr Child Health

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Perniosis during the COVID-19 pandemic: negative anti-SARS-CoV-2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS-CoV-2

Recurrence of previous chilblain lesions during the second wave of COVID-19: can we still doubt the correlation with SARS-CoV-2?

COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient

SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion

Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein

Recurrence of chilblains during a second contact with SARCoV-2: a case report

Relapse of chilblain-like lesions during the second wave of coronavirus 19

Chilblain-like lesions and COVID-19: second wave, second outbreak

Chilblain lesions after COVID-19 mRNA vaccine

Blue toes' following vaccination with Pfizer BNT162b2 mRNA COVID-19 vaccine

BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2

Chilblains is a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France

Chilblains in children in the setting of COVID-19 pandemic

The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Histopathological features of chilblain-like lesions developing in the setting of the COVID-19 pandemic

Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries

Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases

Perniosis: clinical and histopathological analysis

A histologic and immunohistochemical study of chilblains

Comparative analysis of chilblain lupus erythematosus and idiopathic perniosis: histopathologic features and immunohistochemistry for CD123 and CD30

Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic

Chilblains appear as a manifestation of SARS-CoV-2 infection and reveal features of type I interferonopathy and micro-vasculopathy

Histopathological study of a broad spectrum of skin dermatoses in patients affected or highly suspected of infection by COVID-19 in the northern part of Italy: analysis of the many faces of the viral-induced skin diseases in previous and new reported cases

Erythema multiforme-like lesions in children and COVID-19

Acral findings during the COVID-19 outbreak: chilblain-like lesions should be preferred to acroischemic lesions

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue

A viral rash: the impact of COVID-19 infection on the skin

Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection?

Waiting for certainty on Covid-19 antibody tests -at what cost?

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Emerging evidence of the direct association between COVID-19 and chilblains

Interferon-driven deletion of antiviral B cells at the onset of chronic infection

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Concurrent chilblains and retinal vasculitis in a child with COVID-19

New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus

Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic

Histological findings in chilblain lupus-like COVID lesions: in search of an answer to understand their aetiology

Long COVID in the skin: a registry analysis of COVID-19 dermatological duration

Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic

Asymptomatic transmission, the Achilles' heel of current strategies to control Covid-19

Preparing for a responsible lockdown exit strategy

A clinicopathological description of COVID-19-induced chilblains (COVID-toes) correlated with a published literature review